Novel Combo With Engineered NK Cells in Early Trial for Breast Cancer
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
Will a CEO’s Murder Nudge American Healthcare Toward the Unthinkable?
Weight Management Cuts Cardiovascular Risks in Breast Cancer Survivors
AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma
Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations
Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation
Can Tumor Mutational Burden Guide Treatment in Metastatic Breast Cancer?
Mezigdomide Combinations Show Promise in Multiple Myeloma
Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer
Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma
Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
New BCMA-Directed Therapies Show Promise in Multiple Myeloma
Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma
Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity
Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma
The Lifesaving Legacy of Vaccines
Health of Myeloma Patient's Marriage Tied to Recovery After Transplant
Optimizing Sequencing of BCMA-Directed Therapies in Myeloma
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
Advances in ALL at ASH Meeting Include New Blinatumomab Data and More
